A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Elderly Volunteers, Mild-to-moderate Alzheimer's Disease Patients

In brief

This is a two-part multiple dose study in healthy male and female (of non-child bearing potential) elderly volunteers, and in Alzheimer's disease patients, to assess the safety, effects on the body, and blood, CSF, and urine drug levels of AZD3293. AZD3293 is being developed for the treatment of Alzheimer's Disease

Key facts

Study ID
NCT01795339
Run by
AstraZeneca
People needed
47
Starts
2013-03-01
Expected to finish
2014-03-01
Last updated by the study team
2014-04-03

Who can join

Age: 55 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.